Abstract

Follicular helper T (Tfh) cells are essential for the formation of high affinity antibodies after vaccination or infection. Although the signals responsible for initiating Tfh differentiation from naïve T cells have been studied, the signals controlling sequential developmental stages culminating in optimal effector function are not well understood. Here we use fate mapping strategies for the cytokine IL-21 to uncover sequential developmental stages of Tfh differentiation including a progenitor-like stage, a fully developed effector stage and a post-effector Tfh stage that maintains transcriptional and epigenetic features without IL-21 production. We find that progression through these stages are controlled intrinsically by the transcription factor FoxP1 and extrinsically by follicular regulatory T cells. Through selective deletion of Tfh stages, we show that these cells control antibody dynamics during distinct stages of the germinal center reaction in response to a SARS-CoV-2 vaccine. Together, these studies demonstrate the sequential phases of Tfh development and how they promote humoral immunity.

Follicular helper T cells play critical roles in the formation of high affinity antibody responses, but the signals involved in the development of these cells after initial differentiation are poorly understood. Here Podestà, Cavazzoni and colleagues characterise transitionary phases of follicular helper T cell development and how progression through these stages is linked to humoral immunity.

Details

Title
Stepwise differentiation of follicular helper T cells reveals distinct developmental and functional states
Author
Podestà, Manuel A. 1   VIAFID ORCID Logo  ; Cavazzoni, Cecilia B. 2 ; Hanson, Benjamin L. 2 ; Bechu, Elsa D. 2 ; Ralli, Garyfallia 2 ; Clement, Rachel L. 2   VIAFID ORCID Logo  ; Zhang, Hengcheng 2 ; Chandrakar, Pragya 2 ; Lee, Jeong-Mi 2 ; Reyes-Robles, Tamara 3 ; Abdi, Reza 2 ; Diallo, Alos 4 ; Sen, Debattama R. 5   VIAFID ORCID Logo  ; Sage, Peter T. 2   VIAFID ORCID Logo 

 Harvard Medical School, Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Università degli Studi di Milano, Renal Division, Department of Health Sciences, Milano, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822) 
 Harvard Medical School, Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Merck & Co., Inc., Exploratory Science Center, Cambridge, USA (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793) 
 Harvard Medical School, Department of Immunology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Harvard Medical School, Center for Cancer Research, Massachusetts General Hospital, Charlestown, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Pages
7712
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2893289690
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.